Anzeige
Mehr »
Login
Montag, 15.04.2024 Börsentäglich über 12.000 News von 689 internationalen Medien
Im Fokus der Anleger: InnoCan Pharma vor entscheidendem Meilenstein!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2N6VP | ISIN: US04335A1051 | Ticker-Symbol:
NASDAQ
12.04.24
21:59 Uhr
36,300 US-Dollar
0,000
0,00 %
1-Jahres-Chart
ARVINAS INC Chart 1 Jahr
5-Tage-Chart
ARVINAS INC 5-Tage-Chart

Aktuelle News zur ARVINAS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrNovartis (NVS) Inks Deal for ARVN's Prostate Cancer Candidate1.106
FrNovartis gains rights to Arvinas' prostate cancer therapy in deal worth over $1bn95
FrNovartis signs deal for Arvinas' prostate cancer therapy103
FrNovartis adds clinical-stage protein degrader from Arvinas104
DoArvinas inks over $1.0 billion deal with Novartis310
DoArvinas Enters Strategic License Agreement with Novartis for Novel Prostate Cancer Therapy263
DoBiotech Stocks Heat Up As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options176
DoNovartis pays $150M for Arvinas' phase 3-ready prostate cancer protein degrader130
DoArvinas Enters Deal With Novartis For License Of ARV-766, Sale Of AR-V7 Program; Stock Jumps265BASEL (dpa-AFX) - Arvinas, Inc. (ARVN) has entered into an exclusive strategic license agreement with Novartis (NVS) for the worldwide development and commercialization of ARV-766, the company's...
► Artikel lesen
DoArvinas rises on license agreement with Novartis for prostate cancer drug51
DoNovartis licenses Arvinas' cancer drug for up to $1 billion41
DoArvinas Inc.: Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer130- Arvinas to receive a $150 million upfront payment for the license of ARV-766 and the sale of Arvinas' preclinical AR-V7 program, with the potential under the License Agreement for up to $1.01 billion...
► Artikel lesen
DoARVINAS, INC. - 8-K, Current Report2
19.03.Arvinas gets new chief medical head1
18.03.Arvinas names new Chief Medical Officer to advance drug programs1
18.03.ARVINAS, INC. - S-8, Securities to be offered to employees in employee benefit plans1
18.03.Arvinas Inc.: Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer52NEW HAVEN, Conn., March 18, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
► Artikel lesen
18.03.ARVINAS, INC. - 8-K, Current Report1
04.03.Arvinas Inc.: Arvinas to Participate in Upcoming Investor Conferences1
28.02.Navigating 7 Analyst Ratings For Arvinas5
Seite:  Weiter >>
71 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1